CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,840 | -19.1% | 371 | 0.0% | 0.00% | -33.3% |
Q2 2023 | $20,828 | -29.8% | 371 | -43.4% | 0.00% | -25.0% |
Q1 2023 | $29,671 | +109792.6% | 656 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $27 | -99.9% | 656 | 0.0% | 0.00% | -33.3% |
Q3 2022 | $43,000 | +7.5% | 656 | 0.0% | 0.01% | +20.0% |
Q2 2022 | $40,000 | -2.4% | 656 | 0.0% | 0.01% | 0.0% |
Q1 2022 | $41,000 | -18.0% | 656 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $50,000 | +92.3% | 656 | +184.0% | 0.01% | +66.7% |
Q3 2021 | $26,000 | -29.7% | 231 | 0.0% | 0.00% | -25.0% |
Q2 2021 | $37,000 | +32.1% | 231 | 0.0% | 0.00% | +33.3% |
Q1 2021 | $28,000 | -20.0% | 231 | 0.0% | 0.00% | -25.0% |
Q4 2020 | $35,000 | +29.6% | 231 | -27.8% | 0.00% | 0.0% |
Q3 2020 | $27,000 | +50.0% | 320 | -23.8% | 0.00% | +33.3% |
Q1 2020 | $18,000 | -30.8% | 420 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $26,000 | – | 420 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |